News coverage about Ocera Therapeutics (NASDAQ:OCRX) has been trending somewhat negative this week, according to AlphaOne Sentiment. AlphaOne, a unit of Accern, identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ocera Therapeutics earned a daily sentiment score of -0.22 on AlphaOne’s scale. AlphaOne also gave news articles about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.

Insider Buying and Selling by Quarter for Ocera Therapeutics (NASDAQ:OCRX)

A number of equities analysts have issued reports on OCRX shares. Aegis reaffirmed a “buy” rating and set a $3.00 price objective on shares of Ocera Therapeutics in a report on Wednesday, May 24th. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Ocera Therapeutics in a research note on Wednesday, May 10th. Finally, Zacks Investment Research upgraded Ocera Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Thursday, March 23rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $3.90.

Shares of Ocera Therapeutics (NASDAQ:OCRX) opened at 0.96 on Friday. The company’s market capitalization is $25.45 million. The stock’s 50 day moving average price is $1.13 and its 200-day moving average price is $1.39. Ocera Therapeutics has a 1-year low of $0.52 and a 1-year high of $3.15.

Ocera Therapeutics (NASDAQ:OCRX) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.04. Ocera Therapeutics had a negative net margin of 4,416.26% and a negative return on equity of 148.87%. On average, equities analysts predict that Ocera Therapeutics will post ($1.10) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Ocera Therapeutics (OCRX) Receiving Somewhat Negative Press Coverage, Study Finds” was first reported by Financial Market News and is the sole property of of Financial Market News. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at

Ocera Therapeutics Company Profile

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with's FREE daily email newsletter.